← Back
Data updated: Jun 28, 2026
HELSINN HLTHCARE
Specialty Pharmaceuticals
HELSINN HLTHCARE is a specialty pharmaceutical company with 3 FDA-approved products.
2003
Since
3
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
FDA Novel Drug Designations
(2021) 1 Novel 1 Orphan 1 Accelerated 1 Priority Review 1 Fast Track
See 1 novel approval →
2021 TRUSELTIQ (INFIGRATINIB PHOSPHATE) Orphan · Priority Review · Accelerated · Fast Track
HELSINN HLTHCARE's Key Drugs
HELSINN HLTHCARE's core commercial portfolio centers on AKYNZEO — its most strategically important drugs approved in the last 15 years.
HELSINN HLTHCARE's Recent FDA Approvals
New NDA/BLA approvals for HELSINN HLTHCARE over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
HELSINN HLTHCARE's Therapeutic Areas
Disease areas where HELSINN HLTHCARE has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
HELSINN HLTHCARE Pipeline Snapshot
Active clinical trials for HELSINN HLTHCARE across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • AKYNZEO leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling